Deals & Cases

Schellenberg Wittmer advised Bioventure on Series B Financing Round of the Swiss Aphaia Companies


Schellenberg Wittmer advised Bioventure Club Deal Nine GmbH & Co KG on a Series B Financing Round of the Swiss Aphaia Companies, which are clinical stage pharma companies that have developed proprietary treatment methods targeting obesity and associated metabolic diseases.

The team of Schellenberg Wittmer consisted of Oliver Triebold, Elia Claude Schunck, Laura Roth (all Corporate/M&A), Michael Nordin and Roland Wild (both Tax).


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.